
|Articles|May 14, 2014
How BMS is Doing RBM (Risk-Based Monitoring)
Author(s)Guest Blogger
At this year’s Bio IT World Conference, Thomas Verish, Group Director of Data Operations Services at Bristol-Myers Squibb,
Advertisement
At this year’s Bio IT World Conference, Thomas Verish, Group Director of Data Operations Services at Bristol-Myers Squibb, elaborated on BMS’s risk-based monitoring (RBM) pilot, and how they are leveraging data, statistical analysis and personnel to execute RBM.
In this
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Foundayo Under National Priority Voucher Program
2
Trump Administration’s Leadership Carousel Across Key Agencies
3
More Than Just Pricing: MFN’s Impact on Pharma: Q&A with Lindsay Bealor Greenleaf
4
The New Antitrust Era: Why CVS-Style Healthcare Integration is Now the FTC’s Primary Target
5




